Enhancement of sensitivity by bestatin of acute promyelocytic leukemia NB4 cells to all-trans retinoic acid

Hirano, Takeo; Kizaki, Masahiro; Kato, Kuniki; Abe, Fuminori; Masuda, Norio; Umezawa, Kazuo

doi:10.1016/s0145-2126(02)00052-8

Cited by 9 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Hirano et al demonstrated that bestatin enhanced the sensitivity of acute promyelocytic leukemia cells to all-trans retinoic acid. 33 Consistent with those findings, the present data suggested that bestatin enhanced the chemosensitivity of solid tumors to PAC.…”

Section: Discussionsupporting

confidence: 91%

Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo

Yamashita

Kajiyama

Terauchi

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

Aminopeptidase N (APN/CD13), a 150-kDa metalloproteinase, is a multifunctional cell surface aminopeptidase with ubiquitous expression. Recent studies have suggested that APN/CD13 plays an important role in tumor progression in several human malignancies. In the current study, we investigated the role of APN/CD13 in paclitaxel (PAC)-resistance of ovarian carcinoma (OVCA) cells. We first examined the correlation between APN/CD13 expression and IC50 values of PAC in a variety of OVCA cell lines. Next we investigated whether suppression of APN/CD13 using bestatin, an inhibitor of APN/CD13 activity or the siRNA technique influenced PAC-sensitivity in ES-2 cells, which highly express APN/CD13. Moreover, we investigated the effect of bestatin on peritoneal metastasis using nude mice. We found a negative correlation between APN/CD13 expression and chemosensitivity to PAC in various carcinoma cell lines. Subsequently, we found a significant increase in PAC-sensitivity of APN/CD13 expressing OVCA cells by suppression of this enzyme, using the addition of bestatin or the siRNA technique. Furthermore, in a peritoneal metastasis model using nude mice, combination treatment with PAC and bestatin caused a synergistic increase of survival time compared with PAC alone treatment. (mean survival time: 37.7 6 7.0 s and 27.1 6 6.6 days, respectively). The present findings showed that APN/CD13 may be involved in decreased sensitivity to PAC in OVCA cells and that the mechanism of this effect involves its enzyme activity at least in part. APN/CD13 may be a therapeutic target for the treatment of OVCA in combination with chemotherapy. ' 2007 Wiley-Liss, Inc.

show abstract

Section: Discussionsupporting

confidence: 91%

Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo

Yamashita

Kajiyama

Terauchi

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Cheung's group has shown that expression of a considerable number of genes is directly controlled by cis-or trans-acting elements of the genotype (8-10). Many studies have also demonstrated the correlation between gene expression and treatment effect (11)(12)(13)(14)(15)(16)(17)(18)(19). The present study links genotype to gene expression to cell line treatment response and ultimately identified genetic variants that influence drug-induced cytotoxicity.…”

Section: Discussionmentioning

confidence: 63%

A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity

Huang

Duan

Bleibel

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

179

191

View full text Add to dashboard Cite

Large interindividual variance has been observed in sensitivity to drugs. To comprehensively decipher the genetic contribution to these variations in drug susceptibility, we present a genome-wide model using human lymphoblastoid cell lines from the International HapMap consortium, of which extensive genotypic information is available, to identify genetic variants that contribute to chemotherapeutic agent-induced cytotoxicity. Our model inte- HapMap ͉ pharmacogenomics ͉ toxicity ͉ whole-genome association

show abstract

“…292,293 Similarly, treatment of human myeloid U937 and NB4 cell lines with bestatin induced phenotypic changes characteristic of macrophage (U937) or neutrophil (NB4) maturation. 280,293,294…”

Section: A Apn Inhibitors As Modulators Of Cell Growth and Maturationmentioning

confidence: 99%

Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospects

Bauvois¹,

Dauzonne²

2005

Med. Res. Rev.

237

162

View full text Add to dashboard Cite

Aminopeptidase N (APN)/CD13 (EC 3.4.11.2) is a transmembrane protease present in a wide variety of human tissues and cell types (endothelial, epithelial, fibroblast, leukocyte). APN/CD13 expression is dysregulated in inflammatory diseases and in cancers (solid and hematologic tumors). APN/CD13 serves as a receptor for coronaviruses. Natural and synthetic inhibitors of APN activity have been characterized. These inhibitors have revealed that APN is able to modulate bioactive peptide responses (pain management, vasopressin release) and to influence immune functions and major biological events (cell proliferation, secretion, invasion, angiogenesis). Therefore, inhibition of APN/CD13 may lead to the development of anti-cancer and anti-inflammatory drugs. This review provides an update on the biological and pharmacological profiles of known natural and synthetic APN inhibitors. Current status on their potential use as therapeutic agents is discussed with regard to toxicity and specificity.

show abstract

Enhancement of sensitivity by bestatin of acute promyelocytic leukemia NB4 cells to all-trans retinoic acid

Cited by 9 publications

References 29 publications

Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo

Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo

A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity

Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospects

Contact Info

Product

Resources

About